MDM2 and neoplasm: Presently, palbociclib, an inhibitor of CDK4/6, is considered as one of the most significant senescence-inducing compounds.[29] Palbociclib, a selective CDK4/6 inhibitor, stimulates senescence in gastric cancer cells.[30] By combining CDK4/6 inhibitors or aurora kinase A inhibitors with MDM2 inhibitors, senescence can be triggered, followed by SASP-mediated tumor infiltration by cytotoxic T cells and immunological clearance of senescent tumor cells.[31]